Trial Profile
An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms INSIGHTS
- Sponsors AbbVie
- 19 Nov 2022 Status changed from active, no longer recruiting to completed.
- 15 Feb 2022 Planned End Date changed from 31 May 2022 to 31 Dec 2022.
- 29 Dec 2021 Planned End Date changed from 17 Dec 2021 to 31 May 2022.